Kazazian Asset Management LLC Sells 65,842 Shares of Indivior PLC $INDV

Kazazian Asset Management LLC lowered its position in Indivior PLC (NASDAQ:INDV) by 82.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,583 shares of the company’s stock after selling 65,842 shares during the quarter. Kazazian Asset Management LLC’s holdings in Indivior were worth $202,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Indivior by 16.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock worth $71,000 after acquiring an additional 666 shares during the last quarter. Y Intercept Hong Kong Ltd increased its position in shares of Indivior by 17.4% in the second quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock worth $375,000 after purchasing an additional 3,769 shares during the last quarter. Amalgamated Bank bought a new stake in Indivior during the second quarter valued at approximately $61,000. CTC Alternative Strategies Ltd. purchased a new position in Indivior in the 1st quarter worth approximately $96,000. Finally, State of New Jersey Common Pension Fund D bought a new position in shares of Indivior in the 2nd quarter worth $262,000. Institutional investors own 60.33% of the company’s stock.

Indivior Stock Performance

NASDAQ:INDV opened at $30.49 on Monday. Indivior PLC has a fifty-two week low of $7.62 and a fifty-two week high of $32.42. The firm has a market cap of $4.20 billion, a PE ratio of 49.18 and a beta of 0.68. The business has a 50 day moving average price of $25.57 and a 200-day moving average price of $19.73.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.38 by $0.34. The company had revenue of $314.00 million for the quarter, compared to the consensus estimate of $257.66 million. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. Indivior has set its FY 2025 guidance at EPS. Research analysts predict that Indivior PLC will post 1.22 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on INDV shares. HC Wainwright lifted their price objective on shares of Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Piper Sandler reaffirmed an “overweight” rating and set a $41.00 price target (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. Finally, Jefferies Financial Group assumed coverage on shares of Indivior in a research note on Tuesday, July 22nd. They issued a “buy” rating and a $20.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $32.17.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.